DR. GLENN DAVID ROSEN, M.D.
Osteopathic Medicine in Palo Alto, CA
License number
California G57077
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
2
300 Pasteur Dr Stanford University Medical Ctr, Palo Alto, CA 94305
632 Teresi Ln, Los Altos, CA 94024
632 Teresi Ln, Los Altos, CA 94024
Phone
(650) 725-9536
(650) 725-4071 (Fax)
(650) 941-9513
(650) 725-4071 (Fax)
(650) 941-9513
Professional information
Fleet Readiness Directorate - Installation Execution At Space And Naval Warfare Systems Command
Position:
Fleet Readiness Directorate - Installation Execution Manager at Space and Naval Warfare Systems Command
Location:
Greater San Diego Area
Industry:
Military
Work:
Space and Naval Warfare Systems Command
- San Diego, CA since 2012
-
Fleet Readiness Directorate - Installation Execution Manager
US Southern Command
- Bogota 2010 - 2012
-
Naval Section Chief, USMILGROUP Colombia
US THIRD Fleet
- San Diego, CA 2006 - May 2010
-
N5 Asst Chief of Staff (ACOS) - Plans and Policy; Deputy ACOS (N5A), and TSC Officer
Defense Intelligence Agency
- Brazil 2003 - 2006
-
Assistant Naval Attaché, US Defense Attaché Office Rio de Janeiro
Defense Intelligence Agency
- Washington, DC 2001 - 2003
-
Reports Officer, Attache Training, Defense Intelligence Agency (DIA) Washington DC
Hoover Institution
- Palo Alto, CA 2000 - 2001
-
National Security Affairs Fellow
US Pacific Command
- Honolulu, HI 1998 - 2000
-
Joint Exercise Officer
US Navy
- San Diego, CA; Jacksonville, FL; Deployed Globally 1987 - 1997
-
Naval Flight Officer in S-3 Viking aircraft (intermittent tours in this timeframe)
Nations Truce Supervision Organization (UNTSO)
- Ismailia, Egypt; Sinai Peninsula; Jerusalem, Israel 1994 - 1994
-
United Nations Peacekeeper
Office of the Chief of Naval Operations
- The Pentagon 1991 - 1993
-
Action Officer, Office of the Chief of Naval Operations (N51)
Naval Training Command
- Pensacola, Florida Area 1985 - 1987
-
Naval Flight Officer student
NASA
- Johnson Space Center, Houston, TX 1985 - 1985
-
US Navy Space Intern
Education:
Stanford University 2000 - 2001
PhD work, Political Science - International Relations Georgetown University 1991 - 1993
MA, National Security Studies United States Naval Academy 1981 - 1985
BS, Aerospace Engineering
PhD work, Political Science - International Relations Georgetown University 1991 - 1993
MA, National Security Studies United States Naval Academy 1981 - 1985
BS, Aerospace Engineering
Languages:
Spanish, Portuguese
Uses Of Diterpenoid Triepoxides As An Anti-Proliferative Agent
US Patent:
6599499, Jul 29, 2003
Filed:
Aug 22, 2001
Appl. No.:
09/935794
Inventors:
Glenn D. Rosen - Stanford CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Pharmagenesis, Inc. - Palo Alto CA
Pharmagenesis, Inc. - Palo Alto CA
International Classification:
A61B 5055
US Classification:
424 934, 424 9341, 436 64
Abstract:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
Uses Of Diterpenoid Triepoxides As An Anti-Proliferative Agent
US Patent:
6537984, Mar 25, 2003
Filed:
Jun 19, 2001
Appl. No.:
09/884898
Inventors:
Glenn D. Rosen - Stanford CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Pharmagenesis - Palo Alto CA
Pharmagenesis - Palo Alto CA
International Classification:
A61K 3144
US Classification:
514200, 514468
Abstract:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
Uses Of Diterpenoid Triepoxides As An Antiproliferative Agent
US Patent:
2003020, Nov 6, 2003
Filed:
May 27, 2003
Appl. No.:
10/446241
Inventors:
Glenn Rosen - Stanford CA, US
Edwin Lennox - Stanford CA, US
John Musser - San Carlos CA, US
Edwin Lennox - Stanford CA, US
John Musser - San Carlos CA, US
International Classification:
A61K031/365, A61K049/00
US Classification:
424/009340, 514/468000
Abstract:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
Glenn David Rosen, Stanford CA
Specialties:
Internal Medicine, Pulmonary Disease, Critical Care Medicine, Surgery
Work:
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305 Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304
300 Pasteur Dr, Stanford, CA 94305 Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304
Education:
University of Pennsylvania(1983)
Uses Of Diterpenoid Triepoxides As An Anti-Proliferative Agent
US Patent:
6294546, Sep 25, 2001
Filed:
Aug 30, 1999
Appl. No.:
9/385917
Inventors:
Glenn D. Rosen - Stanford CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Edwin S. Lennox - Stanford CA
John H. Musser - San Carlos CA
Assignee:
The Broad of Trustees of the Leland Stanford Junior University - Palo Alto CA
Pharmagenesis - Palo Alto CA
Pharmagenesis - Palo Alto CA
International Classification:
A61K 3144, A61K 3134
US Classification:
514280
Abstract:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
Uses Of Diterpenoid Triepoxides As An Anti-Proliferative Agent
US Patent:
6949510, Sep 27, 2005
Filed:
Jan 10, 2003
Appl. No.:
10/340101
Inventors:
Glenn D. Rosen - Stanford CA, US
Edwin S. Lennox - Stanford CA, US
John H. Musser - San Carlos CA, US
Edwin S. Lennox - Stanford CA, US
John H. Musser - San Carlos CA, US
Assignee:
Pharmagenesis - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K038/00, A61K031/44, A61K031/34
US Classification:
514 11, 514291, 514468
Abstract:
Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
Treatment And Prevention Of Diffuse Parenchymal Lung Disease By Selective Active-Site Mtor Inhibitors
US Patent:
2011031, Dec 29, 2011
Filed:
Jun 28, 2011
Appl. No.:
13/171441
Inventors:
Glenn D. Rosen - Los Altos CA, US
Wen-Teh Chang - San Jose CA, US
Wen-Teh Chang - San Jose CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/519, A61P 29/00, A61P 11/00, A61P 17/00, A61K 31/496, A61K 31/5377
US Classification:
5142325, 5142621, 51425303, 5142342
Abstract:
Embodiments are related to new uses for selective active-site mTOR inhibitors in treating or preventing pulmonary fibrosis in diffuse parenchymal lung disease (DPLD) patients, such as a DPLD of environmental cause, a collagen vascular disease (e.g., scleroderma and rheumatoid arthritis), an idiopathic interstitial pneumonia (e.g., idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia), and sarcoidosis.
Combined Therapy Of Diterpenoid Triepoxides And Death Domain Receptor Ligands For Synergistic Killing Of Tumor Cells
US Patent:
6329148, Dec 11, 2001
Filed:
Feb 15, 2000
Appl. No.:
9/505250
Inventors:
Glenn D. Rosen - Stanford CA
Peter Kao - Stanford CA
Peter Kao - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford University - Palo Alto CA
International Classification:
C12Q 168, A01N 6500, A61K 4800
US Classification:
435 6
Abstract:
A synergistic combination of ligands that interact with death domain receptors, and diterpenoid triepoxides is used to increase tumor cell killing by induction of apoptosis. Ligands useful in the invention include TRAIL, TNF-. alpha. , analogs thereof, stabilized multimers thereof, mimetics, etc. Of particular interest are combined therapy with the diterpenoid triepoxides triptolide and derivatives and analogs thereof.
Treatment And Prevention Of Diffuse Parenchymal Lung Disease By Selective Active-Site Mtor Inhibitors
US Patent:
2014003, Feb 6, 2014
Filed:
Apr 21, 2013
Appl. No.:
13/867123
Inventors:
Glenn D. Rosen - Los Altos CA, US
Wen-Teh Chang - San Jose CA, US
Wen-Teh Chang - San Jose CA, US
Assignee:
The Board of Trustees of the Leland Standford Junior University - Palo Alto CA
International Classification:
A61K 31/5377, A61K 49/00, A61K 31/519
US Classification:
424 92, 5142621, 5142325
Abstract:
Provided herein are methods for treating or preventing pulmonary fibrosis in subjects suffering from diffuse parenchymal lung diseases using selective active-site mTOR inhibitors.